Dina Pharma was founded by a team of world-renowned doctors, scientists, and academics with a singular goal: to improve the quality of life of patients suffering from Parkinson's disease. We are introducing an innovative, new therapy, DPI-289, which improves efficacy and reduces the side effects of the primary treatment for Parkinson's disease.
What is Parkinson's Disease? Parkinson's disease (PD) is a chronic and progressive movement disorder involving the loss of dopamine-producing neurons in the brain. Nearly one million people in the U.S. live with Parkinson's disease, and approximately five million around the world.
As PD progresses, dopamine production declines, leaving a person unable to control movement normally. Primary motor signs of Parkinson’s disease include the following:
bradykinesia or slowness of movement;
tremor of the hands, arms, legs, jaw and face;
rigidity or stiffness of the limbs and trunk;
postural instability or impaired balance and coordination.
How is PD Currently Treated? There is no cure for PD at present. The "gold standard" treatment of PD is a drug called Levodopa or L-DOPA. For many patients, L-DOPA improves motor symptoms. However, L-DOPA has significant, negative side effects for many patients, in particular, dyskinesia. Dyskinesia involvesinvoluntary movements, spasms, and tics. These patients often face a terrible choice between treating their Parkinson's symptoms and enduring Levodopa-induced dyskinesia.
Dina Pharma is developing a treatment for Levodopa-Induced Dyskinesia (LID), for which no other approved therapies exist.